Enterprise Europe Network

An Israeli company that has developed an innovative, minimally invasive therapeutic technology for treating bladder cancer (NMIBC) is looking for distributors

Country of origin:
Country: 
ISRAEL
Opportunity:
External Id: 
BOIL20191105001
Published
20/11/2019
Last update
10/06/2020
Expiration date
10/06/2021

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Internal medicine
Oncology
EXPRESS YOUR INTEREST

Summary

Summary: 
The Israeli medical device company has over 20 years of experience in the fields of urology and oncology. The device is based on minimally invasive therapeutic technology. It uses controlled RF (radio frequency) radiation, along with thermos-chemotherapy. The treatment is provided in medical facilities worldwide. The company has an R&D team and provides technical support. They are seeking for distributors, as well as to establish commercial agency agreements with healthcare providers.

Description

Description: 

The company is a well-known manufacturer and supplier of medical devices in Israel, with about 20 years of experience in the local market.

Their clientele covers all types of organisations and stakeholders in the Israeli medical and life science sectors, including the Ministry of Health, hospitals, medical institutions and clinics, as well as universities and research centres.

The staff, which consists of 12 employees, includes professional, skilled employees in the fields of electrical and mechanical engineering, software and QA, product management, customer service and logistics. In addition, the clinical team includes trained specialists who provide medical support to urology clinics and manages clinical trials around the world.

The company is focused on developing minimally invasive therapeutic technologies, specifically in the field of urology and oncology. The leading technology is a minimally invasive technology that is using non-ionizing microwave radiation and chemotherapy for the treatment of non-muscle invasive bladder cancer. This treatment is based on controlled hyperthermia (through the RF radiation) of the bladder walls, along with installations of the bladder with chemotherapy.

The patient is treated on an outpatient basis in a series of weekly one-hour sessions with no need for anesthesia. The treatment provides reduced recurrence and progression rates and reduced need for operations. The treatment improves patients’ quality of life and is practical and easy to perform by qualified personnel.

The technology is used in medical centres around the world. It has been proven safe and efficacious in the treatment of non-muscle invasive bladder cancer in numerous routine treatment studies and clinical trials. It is CE certified since 2001 and has been recommended by the European Association of Urology’s Guidelines and by NICE.

The company’s technology can be used by healthcare providers, such as medical centres, hospitals and clinics. In order to globally expand the use of the device, the company is looking for distributors of medical devices, preferably from the fields of urology and oncology. As well, the company would like to establish commercial agency agreements with healthcare providers, interested in the device.

Advantages & innovations

Cooperation plus value: 
- The technology device is CE certified for Medical Device Directive (Directive 93/42/EEC) since 2001 - The device is a patented technology and is complying with various standards: IEC 60601-1 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance IEC 60601-1-2 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances IEC 60601-2-6Medical electrical equipment - Part 2-6: Particular requirements for the basic safety and essential performance of microwave therapy equipment IEC 60601-2-24 Medical electrical equipment - Part 2-24: Particular requirements for the basic safety and essential performance of infusion pumps and controllers -The company is currently certified by BSI for both CE mark EN ISO 13485:2016 -The technology has been recommended by the European Association of Urology’s Guidelines and by NICE for the treatment of non-muscle invasive bladder cancer -The technology has over 50 clinical journal articles written about it

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
In order to globally expand the use of the device, the company is looking for distributors of medical devices, preferably from the fields of urology and oncology. As well, the company would like to cooperate with healthcare providers, interested in the device, under commercial agency agreements.

Type and size

Cooperation task: 
SME 11-50,SME <10,SME 51-250